BACKGROUND: Prognostic impact of tumour marker index (TMI) based on preoperative serum carcinoembryonic antigen (CEA) and CYFRA 21-1 in non-small cell lung cancer (NSCLC) was examined using patients with a follow-up period more than 5 years. PATIENTS AND METHODS: Two hundred and ninety-three consecutive NSCLC patients were reviewed retrospectively, and any patients with follow-up periods less than 5 years were omitted. RESULTS: The 5-year survival of the patients with normal and high serum CEA levels was 71.52% and 48.41%, respectively (p<0.0001). The 5-year survival of the patients with a high serum CYFRA 21-1 level was 39.66%, which was significantly poorer compared with that of the patients with a normal serum CYFRA 21-1 level (66.95%, p<0.0001). There was a 5-year-survival rate of 72.28% in patients with a TMI less than or equal to 1.0 compared to only 37.08% in patients with a TMI greater than 1.0 (p<0.0001). Both univariate and multivariate analyses indicated the independent prognostic impact of TMI. CONCLUSIONS: TMI may be useful for predicting the prognosis of NSCLC patients.
BACKGROUND: Prognostic impact of tumour marker index (TMI) based on preoperative serum carcinoembryonic antigen (CEA) and CYFRA 21-1 in non-small cell lung cancer (NSCLC) was examined using patients with a follow-up period more than 5 years. PATIENTS AND METHODS: Two hundred and ninety-three consecutive NSCLCpatients were reviewed retrospectively, and any patients with follow-up periods less than 5 years were omitted. RESULTS: The 5-year survival of the patients with normal and high serum CEA levels was 71.52% and 48.41%, respectively (p<0.0001). The 5-year survival of the patients with a high serum CYFRA 21-1 level was 39.66%, which was significantly poorer compared with that of the patients with a normal serum CYFRA 21-1 level (66.95%, p<0.0001). There was a 5-year-survival rate of 72.28% in patients with a TMI less than or equal to 1.0 compared to only 37.08% in patients with a TMI greater than 1.0 (p<0.0001). Both univariate and multivariate analyses indicated the independent prognostic impact of TMI. CONCLUSIONS:TMI may be useful for predicting the prognosis of NSCLCpatients.
Authors: Suresh S Ramalingam; Mikhail Shtivelband; Ross A Soo; Carlos H Barrios; Anatoly Makhson; José G M Segalla; Kenneth B Pittman; Petr Kolman; Jose R Pereira; Gordan Srkalovic; Chandra P Belani; Rita Axelrod; Taofeek K Owonikoko; Qin Qin; Jiang Qian; Evelyn M McKeegan; Viswanath Devanarayan; Mark D McKee; Justin L Ricker; Dawn M Carlson; Vera A Gorbunova Journal: J Clin Oncol Date: 2015-01-05 Impact factor: 44.544